<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801771</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003</org_study_id>
    <secondary_id>1U01DC019279-01</secondary_id>
    <nct_id>NCT04801771</nct_id>
  </id_info>
  <brief_title>Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea</brief_title>
  <official_title>Effects of Hypoglossal Nerve Stimulation on Cognition and Language in Down Syndrome and Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inspire Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Deafness and Other Communication Disorders (NIDCD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Inspire Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, single-arm study conducted under a common implant and follow-up&#xD;
      protocol. The objective will be to follow fifty-seven (57) adolescents and young adults&#xD;
      (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and&#xD;
      post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway&#xD;
      Stimulation (UAS) System. The study is being conducted in order to evaluate objective change&#xD;
      in cognition and expressive language after implant and therapy with the Inspire UAS System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single-arm study conducted under a common implant and follow-up&#xD;
      protocol. The objective will be to follow fifty-seven (57) adolescents and young adults&#xD;
      (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and&#xD;
      post-adenotonsillectomy, for 12 months after undergoing implant of the Inspire Upper Airway&#xD;
      Stimulation (UAS) System. The study is being conducted in order to evaluate objective change&#xD;
      in cognition and expressive language after implant and therapy with the Inspire UAS System.&#xD;
&#xD;
      Prior to implant subjects will be required to meet eligibility criteria, complete quality of&#xD;
      life questionnaires and undergo neurocognitive testing (NCT) and expressive language&#xD;
      sampling. Eligibility criteria will be determined via review of medical records, an in-lab&#xD;
      polysomnography (sleep study), and a drug-induced sleep endoscopy (DISE).&#xD;
&#xD;
      After implant of the Inspire UAS System, subjects will undergo five (5) study visits. Four&#xD;
      (4) of the visits will include an in-lab sleep study (PSG). Follow-up expressive language&#xD;
      sampling and neurocognitive testing will be performed at 6 months post-implant. Follow-up&#xD;
      quality of life questionnaires will be completed at 12 months post-implant.&#xD;
&#xD;
      Subjects will conclude their participation in the study at the end of their 12 month study&#xD;
      visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intelligence using the Kaufman Brief Intelligence Scale (KBIT-2)</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Change in the Intelligence Quotient Standard Score of at least 0.5 standard deviation from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in attention using the Wechsler Intelligence Scale</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Change in Cancellation scaled score of at least 0.5 standard deviation from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in processing speed using the Cambridge Neuropsychological Test Automated Battery (CANTAB)</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Change in RTIFMDRT and RTIFMDMT raw scores of at least 0.5 standard deviation from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in executive functioning using the Delis-Kaplan Executive Functioning System (DKEFS)</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Change in Category Functioning scaled score of at least 0.5 standard deviation from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in learning and memory using the Cambridge Neuropsychological Test Automated Battery - Paired Associates Learning</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Change in PAL-TEA raw score of at least 0.5 standard deviation from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in language using Expressive Language Sampling</measure>
    <time_frame>6 Months post-implant</time_frame>
    <description>Change in % of unintelligible C-units, number of different word roots and mean length of C-units in morphemes of at least 0.5 standard deviation from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of procedure and device-related adverse events</measure>
    <time_frame>Implant through 12 Months post-implant</time_frame>
    <description>Procedure and device-related adverse events will be collected in order to profile the safety of hypoglossal nerve stimulation in adolescents. Number and percent of procedure and device-related adverse events will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Obstructive Sleep Apnea (OSA)</measure>
    <time_frame>3, 6, 12 Months post-implant</time_frame>
    <description>Change in sleep apnea will be measured using standard in-lab PSG measures including oxygen level, partial and complete airway obstruction, and arousals. Improvement will be defined as a 50% or more decrease in AHI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as measured by OSA-18 and ESS-CHAD questionnaires</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>Quality of life improvements will be measured using the OSA-18 and ESS-CHAD. Mean scores for each questionnaire will be reported at baseline and 12 months post-implant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Down Syndrome</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Subjects implanted with Inspire UAS System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who meet eligibility criteria will be implanted with the Inspire Upper Airway Stimulation (UAS) System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Inspire Upper Airway Stimulation (UAS) System</intervention_name>
    <description>The Inspire UAS System is an implantable device that provides hypoglossal nerve stimulation for the treatment of obstructive sleep apnea.</description>
    <arm_group_label>Subjects implanted with Inspire UAS System</arm_group_label>
    <other_name>Hypoglossal nerve stimulation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Down syndrome&#xD;
&#xD;
          -  Age 10-21 years&#xD;
&#xD;
          -  Prior adenotonsillectomy&#xD;
&#xD;
          -  Severe OSA (AHI &gt; 10, AHI &lt; 50, no more than 25% AHI attributable to central events)&#xD;
             based on prior in-lab PSG performed after adenotonsillectomy and within 18 months of&#xD;
             enrollment&#xD;
&#xD;
          -  Approval from at least two of the three physician reviewers based upon the results of&#xD;
             a routine drug-induced sleep endoscopy (DISE) having occurred within 12 months of&#xD;
             enrollment&#xD;
&#xD;
          -  Subjects must have either tracheotomy or be ineffectively treated with CPAP due to&#xD;
             non-compliance, discomfort, un-desirable side effects, persistent symptoms despite&#xD;
             compliance use, or refusal to use the device&#xD;
&#xD;
          -  Children and their parents/guardians must be willing to have stimulation hardware&#xD;
             permanently implanted, and be willing to participate in follow-up visits,&#xD;
             postoperative PSG, and questionnaire completion&#xD;
&#xD;
          -  Children's parents/guardians must complete a questionnaire confirming that their child&#xD;
             is capable of communicating feelings of pain or discomfort. They must also confirm&#xD;
             they are able to assess their child for adverse effects related to device implantation&#xD;
&#xD;
          -  Children and their parents/guardians must be proficient in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) above the 95th percentile for subject's age&#xD;
&#xD;
          -  Circumferential airway collapse at the level of the velopharynx observed during DISE&#xD;
&#xD;
          -  Other medical conditions resulting in medical instability (eg. congestive heart&#xD;
             failure, recent open heart surgery, immunosuppression, or chronic lung disease or&#xD;
             aspiration)&#xD;
&#xD;
          -  Presence of another medical condition requiring future magnetic resonance imaging&#xD;
             (MRI) of the chest&#xD;
&#xD;
          -  Patients with another implantable device which could interact unintentionally with the&#xD;
             Inspire system&#xD;
&#xD;
          -  Any contraindication for general anesthesia&#xD;
&#xD;
          -  History of bleeding or clotting disorders and those on blood thinning or NSAID&#xD;
             medications for the week prior to implantation surgery. Subjects will be asked to&#xD;
             refrain from the use of NSAIDS for two weeks after implantation or any revision&#xD;
             surgeries&#xD;
&#xD;
          -  Subject is currently taking muscle relaxant medication&#xD;
&#xD;
          -  Life expectancy less than 12 months&#xD;
&#xD;
          -  Subject's inability to communicate pain or discomfort to their caretaker/parent, based&#xD;
             on parental or investigator assessment&#xD;
&#xD;
          -  Nonverbal candidates will be excluded due to an inability to complete testing&#xD;
             procedures including expressive language sampling&#xD;
&#xD;
          -  Subjects with a co-occurring diagnosis of autism spectrum disorder&#xD;
&#xD;
          -  Subjects that have a positive Î²-HCG&#xD;
&#xD;
          -  Subjects deemed unfit for participation by the investigator for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Hartnick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Massachusetts Eye and Ear Infirmary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mike Swierzewski</last_name>
    <phone>612-325-9723</phone>
    <email>mikeswierzewski@inspiresleep.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gwen Gimmestad</last_name>
    <phone>763-392-9966</phone>
    <email>gwengimmestad@inspiresleep.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital (Mass Eye &amp; Ear Infirmary)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odeta Dyrmishi, MPA</last_name>
      <email>Odeta_Dyrmishi@meei.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Chris Hartnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Skotko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoglossal nerve stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Down Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

